Personalis to Present NeXT Personal® Data at ESMO 2026
Personalis, Inc. announced that it will present new data from its NeXT Personal® ultrasensitive ctDNA test at the upcoming European Society for Medical Oncology (ESMO) conference.
Stocks · News reference
Personalis, Inc. announced its financial and operational results for the third quarter ended September 30, 2026, and highlighted the commercial launch of its NeXT Personal Real-Time Variant Tracker.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Personalis, Inc. announced that it will present new data from its NeXT Personal® ultrasensitive ctDNA test at the upcoming European Society for Medical Oncology (ESMO) conference.
Tempus AI expands its collaboration with Moderna and Merck to support sample collection and NGS services for intismeran autogene and Keytruda.
Filed: 2026-10-06 AccNo: 0001193125-26-415547 Size: 156 KB Item 8.01: Other Events
Analysts downgraded Gentex, Personalis, Goosehead Insurance, cutting ratings and several price targets.
BTIG analyst Mark Massaro downgrades Personalis (NASDAQ:PSNL) from Buy to Neutral.
Law firm Brodsky & Smith announced investigations into four major merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and ensure fair value for shareholders. The investigations involve Centerspace's acquisition by Independence Realty Trust, Fulcrum Therapeutics' acquisition by Slate Medicines, Weave Communications' acquisition by Francisco Partners, and Personalis' acquisition by Tempus AI.